889126-15-2

Upstream product

• 23345-80-4 3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
• 889126-05-0 5-O-acetyl-3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
• 889126-06-1 2,5-di-O-acetyl-3-azido-1-(6-chloropurin-9-yl)-β-D-1,3-dideoxyribofuranose 
• 889126-09-4 N⁶-(3-iodobenzyl)-9-(3-azido-3-deoxy-β-D-ribofuranosyl)adenine 
• 179530-74-6 1,2,5-tri-O-acetyl-3-azido-3-deoxy-D-ribofuranose 
• 889126-12-9 N⁶-(3-iodobenzyl)-9-(3-azido-2,5-di-O-t-butyldimethylsilyl-3-deoxy-β-D-ribofuranosyl)adenine 

Downstream Products

• 889126-18-5 N⁶-(3-iodobenzyl)-9-[3-(3-chloroacetylureido)-2,5-di-O-t-butyldimethylsilyl-3-deoxy-β-D-ribofuranosyl]adenine 
• 889126-21-0 N⁶-(3-iodobenzyl)-9-(2,5-di-O-t-butyldimethylsilyl-3-deoxy-3-ureido-β-D-ribofuranosyl)adenine 

Relevant academic research and scientific papers

Synthesis of N6-Substituted 3′-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptor

Several N6-substituted 3′-ureidoadenosine derivatives were efficiently synthesized starting from D-glucose for the development of H272E mutant A3 adenosine receptor (AR) agonists. Among compounds tested, 3′-ureido-N6-(3-iodobenzyl)adenosine (2c) exhibited

Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists

An alternative approach to overcome the inherent lack of specificity of conventional agonist therapy can be the reengineering of the GPCRs and their agonists. A reengineered receptor (neoceptor) could be selectively activated by a modified agonist, but no

Synthesis of 3′-ureidoadenosine analogues and their binding affinity to the A3 adenosine receptor

Novel 3′-ureidoadenosine analogues were synthesized from 1,2:5,6-di-0-isopropylidene-D-glucose in order to lead to stronger hydrogen bonding at the A3 adenosine receptor than the corresponding 3-aminoadenosine derivatives. However, all synthesi